PARP1 and cancer: We therefore evaluated the mutation status of 22 genes with either established, emerging, or potential roles in either the HR repair pathway or PARP inhibitor sensitivity, first in a pan cancer analysis of over 55,000 patients compiled from several genomic databases, followed by a more focused analysis of The Cancer Genome Atlas (TCGA) cohort, which allowed for more insight into disease-specific mutation frequencies.